Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b trial to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DCPH
CUSIPN/A
Phone781-209-6400
Debt
Debt-to-Equity Ratio0.01
Current Ratio11.12
Quick Ratio11.12
Price-To-Earnings
Trailing P/E Ratio-12.99
Forward P/E Ratio-14.18
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.64 per share
Price / Book6.71
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees65
Outstanding Shares37,540,000
Market Cap$1,409.96
Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions
What is Deciphera Pharmaceuticals' stock symbol?
Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."
How were Deciphera Pharmaceuticals' earnings last quarter?
Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) released its earnings results on Tuesday, May, 8th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.62) by $0.04. View Deciphera Pharmaceuticals' Earnings History.
What price target have analysts set for DCPH?
7 analysts have issued 1-year target prices for Deciphera Pharmaceuticals' shares. Their forecasts range from $33.00 to $65.00. On average, they anticipate Deciphera Pharmaceuticals' share price to reach $50.8333 in the next year. This suggests a possible upside of 34.2% from the stock's current price. View Analyst Ratings for Deciphera Pharmaceuticals.
What is the consensus analysts' recommendation for Deciphera Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Deciphera Pharmaceuticals' key competitors?
Some companies that are related to Deciphera Pharmaceuticals include Dr.Reddy's Laboratories (RDY), United Therapeutics (UTHR), Loxo Oncology (LOXO), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Array Biopharma (ARRY), OPKO Health (OPK) and Ironwood Pharmaceuticals (IRWD).
Who are Deciphera Pharmaceuticals' key executives?
Deciphera Pharmaceuticals' management team includes the folowing people:
- Dr. Michael D. Taylor, Pres, CEO & Director (Age 63)
- Dr. Daniel L. Flynn, Founder & Chief Scientific Officer (Age 63)
- Mr. Christopher J. Morl, Chief Bus. Officer (Age 59)
- Mr. Thomas Patrick Kelly, Chief Financial Officer (Age 47)
- Mr. Thomas W. Fredrick, Head of Legal Affairs
When did Deciphera Pharmaceuticals IPO?
(DCPH) raised $101 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.
Has Deciphera Pharmaceuticals been receiving favorable news coverage?
News coverage about DCPH stock has been trending somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Deciphera Pharmaceuticals earned a news impact score of 0.18 on Accern's scale. They also assigned press coverage about the company an impact score of 44.78 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Deciphera Pharmaceuticals?
Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Deciphera Pharmaceuticals' stock price today?
One share of DCPH stock can currently be purchased for approximately $37.87.
How big of a company is Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals has a market capitalization of $1.41 billion. The company earns $-50,280,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Deciphera Pharmaceuticals employs 65 workers across the globe.
How can I contact Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals' mailing address is 500 Totten Pond Road, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]
MarketBeat Community Rating for Deciphera Pharmaceuticals (NASDAQ DCPH)
MarketBeat's community ratings are surveys of what our community members think about Deciphera Pharmaceuticals and other stocks. Vote "Outperform" if you believe DCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
